Abstract
Background: Coronary Heart Disease (CHD) patients are at risk of suffering from drug interactions, leading to a higher risk of mortality and morbidity among these patients. This study aims to identify the potential drug-drug interactions (PDDIs) and CHD patients' related factors.
Methods: A cross-sectional study was performed among the CHD patients to identify the PDDIs from 2014 to 2017 at a Secondary Hospital. The PDDIs were categorized according to the interaction mechanism, onset, severity, and documentation.
Results: Among 91 CHD patients, 151 PDDIs were identified consisting of pharmacokinetics mechanism and delayed onset, 50.33%, and 83.44%, respectively. Furthermore, there was a correlation between the number of PDDIs and the number of drugs (r = 0.496; p < 0.001).
Conclusion: This study revealed that the more the drugs were prescribed to CHD patients, the more the PDDIs risk would occur. The regular monitoring of the CHD patient’s prescriptions is noteworthy to avoid the PDDIs.
Keywords: Coronary heart disease, potential drug-drug interactions, cross-sectional study, drug-drug interaction, mortality, pharmacodynamics.
Graphical Abstract
[1]
Khan MA, Hashim MJ, Mustafa H, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus 2020; 12(7): e9349.
[2]
Uli RE, Satyana RPU, Zomer E, Magliano D, Liew D, Ademi Z. Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. BMJ Open 2020; 10(9): e039221.
[http://dx.doi.org/10.1136/bmjopen-2020-039221] [PMID: 32912956]
[http://dx.doi.org/10.1136/bmjopen-2020-039221] [PMID: 32912956]
[3]
Ismail M, Iqbal Z, Khan MI, et al. Frequency, levels and predictors of potential drug-drug interactions in a pediatrics ward of a teaching hospital in Pakistan. Trop J Pharm Res 2013; 12(3): 401-6.
[http://dx.doi.org/10.4314/tjpr.v12i3.19]
[http://dx.doi.org/10.4314/tjpr.v12i3.19]
[4]
Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: A review of the recent literature. Drug Saf 2007; 30(5): 379-407.
[http://dx.doi.org/10.2165/00002018-200730050-00003] [PMID: 17472418]
[http://dx.doi.org/10.2165/00002018-200730050-00003] [PMID: 17472418]
[5]
Kothari N, Ganguly B. Potential drug - drug interactions among medications prescribed to hypertensive patients. J Clin Diagn Res 2014; 8(11): HC01-4.
[http://dx.doi.org/10.7860/JCDR/2014/10032.5091] [PMID: 25584241]
[http://dx.doi.org/10.7860/JCDR/2014/10032.5091] [PMID: 25584241]
[6]
Bushra R, Aslam N, Khan AY. Food-drug interactions. Oman Med J 2011; 26(2): 77-83.
[http://dx.doi.org/10.5001/omj.2011.21] [PMID: 22043389]
[http://dx.doi.org/10.5001/omj.2011.21] [PMID: 22043389]
[7]
Nusair MB, Al-Azzam SI, Arabyat RM, Amawi HA, Alzoubi KH, Rabah AA. The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. Saudi Pharm J 2020; 28(2): 155-60.
[http://dx.doi.org/10.1016/j.jsps.2019.11.009] [PMID: 32042253]
[http://dx.doi.org/10.1016/j.jsps.2019.11.009] [PMID: 32042253]
[8]
Patel VK, Acharya LD, Rajakannan T, Surulivelrajan M, Guddattu V, Padmakumar R. Potential drug interactions in patients admitted to cardiology wards of a south Indian teaching hospital. Australas Med J 2011; 4(1): 9-14.
[http://dx.doi.org/10.4066/AMJ.2011.450] [PMID: 23393498]
[http://dx.doi.org/10.4066/AMJ.2011.450] [PMID: 23393498]
[9]
Diksis N, Melaku T, Assefa D, Tesfaye A. Potential drug-drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia. SAGE Open Med 2019; 7: 2050312119857353.
[http://dx.doi.org/10.1177/2050312119857353] [PMID: 31217972]
[http://dx.doi.org/10.1177/2050312119857353] [PMID: 31217972]
[10]
Murtaza G, Khan MYG, Azhar S, Khan SA, Khan TM. Assessment of potential drug-drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J 2016; 24(2): 220-5.
[http://dx.doi.org/10.1016/j.jsps.2015.03.009] [PMID: 27013915]
[http://dx.doi.org/10.1016/j.jsps.2015.03.009] [PMID: 27013915]
[11]
Passarelli MCG, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: Inappropriate prescription is a leading cause. Drugs Aging 2005; 22(9): 767-77.
[http://dx.doi.org/10.2165/00002512-200522090-00005] [PMID: 16156680]
[http://dx.doi.org/10.2165/00002512-200522090-00005] [PMID: 16156680]
[12]
Schober P, Boer C, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. Anesth Analg 2018; 126(5): 1763-8.
[http://dx.doi.org/10.1213/ANE.0000000000002864] [PMID: 29481436]
[http://dx.doi.org/10.1213/ANE.0000000000002864] [PMID: 29481436]
[13]
Yuliani F, Oenzil F, Iryani D. The relationship of various risk factors to the incidence of coronary heart disease in patients with type 2 diabetes mellitus. J Kesehatan Andalas 2014; 3(1)
[14]
Dam V, van der Schouw YT, Onland-Moret NC, et al. Association of menopausal characteristics and risk of coronary heart disease: A pan-European case-cohort analysis. Int J Epidemiol 2019; 48(4): 1275-85.
[http://dx.doi.org/10.1093/ije/dyz016] [PMID: 30796459]
[http://dx.doi.org/10.1093/ije/dyz016] [PMID: 30796459]
[15]
Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: A global assessment of the effect of ageing between 1980 and 2010. BMJ Glob Health 2017; 2(2): e000298.
[http://dx.doi.org/10.1136/bmjgh-2017-000298] [PMID: 28589033]
[http://dx.doi.org/10.1136/bmjgh-2017-000298] [PMID: 28589033]
[16]
Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016; 4(13): 256.
[http://dx.doi.org/10.21037/atm.2016.06.33] [PMID: 27500157]
[http://dx.doi.org/10.21037/atm.2016.06.33] [PMID: 27500157]
[17]
Indonesian Heart Association. Pedoman tatalaksana hipertensi pada
penyakit kardiovaskular. 2015. Availble: http://www.inaheart.org/
upload/image/Pedoman_TataLaksna_hipertensi_pada_penyakit_
Kardiovaskular_2015.pdf
[18]
Anastasius M, Lau JK, Hyun K, et al. The underutilisation of dual antiplatelet therapy in acute coronary syndrome. Int J Cardiol 2017; 240: 30-6.
[http://dx.doi.org/10.1016/j.ijcard.2017.04.077] [PMID: 28476519]
[http://dx.doi.org/10.1016/j.ijcard.2017.04.077] [PMID: 28476519]
[19]
Bian L, Qiu M, Li Y, et al. Impact of extended dual antiplatelet therapy on clinical prognosis in acute coronary syndrome patients with intermediate or high ischemic risk defined by the GRACE score. Catheter Cardiovasc Interv 2020; 95(S1)(Suppl. 1): 665-73.
[http://dx.doi.org/10.1002/ccd.28736] [PMID: 31957965]
[http://dx.doi.org/10.1002/ccd.28736] [PMID: 31957965]
[20]
Wang MT, Su CY, Chan AL, Lian PW, Leu HB, Hsu YJ. Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: A population-based study. Br J Clin Pharmacol 2010; 70(2): 258-67.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03687.x] [PMID: 20653679]
[http://dx.doi.org/10.1111/j.1365-2125.2010.03687.x] [PMID: 20653679]
[21]
Dasgupta A. Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring: A Comprehensive Guide. Wiley: Hoboken 2012.
[http://dx.doi.org/10.1002/9781118347867]
[http://dx.doi.org/10.1002/9781118347867]
[22]
MacLeod-Glover N, Mink M, Yarema M, Chuang R. Digoxin toxicity: Case for retiring its use in elderly patients? Can Fam Physician 2016; 62(3): 223-8.
[PMID: 26975913]
[PMID: 26975913]
[23]
Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004; 109(24): 2959-64.
[http://dx.doi.org/10.1161/01.CIR.0000132482.95686.87] [PMID: 15210613]
[http://dx.doi.org/10.1161/01.CIR.0000132482.95686.87] [PMID: 15210613]
[24]
Tatro DS. Drug Interaction Facts: The Authority on Drug Interactions. 1st ed. California: Wolters Kluwer Health 2010.
[25]
Medscape. Drug Interaction Checker 2018 [updated 27th June
2018. 2018. Availble: http://www.reference.medscape.com/drug-interactionchecker
[26]
Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109(11): 1335-8.
[http://dx.doi.org/10.1161/01.CIR.0000124581.18191.15] [PMID: 15023882]
[http://dx.doi.org/10.1161/01.CIR.0000124581.18191.15] [PMID: 15023882]
[28]
Charpentier T, Ferdynus C, Lair T, et al. Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis. PLoS One 2020; 15(5): e0232768.
[http://dx.doi.org/10.1371/journal.pone.0232768] [PMID: 32365100]
[http://dx.doi.org/10.1371/journal.pone.0232768] [PMID: 32365100]
[29]
Massberg S, Polzin A. Update ESC-guideline 2017: Dual antiplatelet therapy. Dtsch Med Wochenschr 2018; 143(15): 1090-3.
[PMID: 30060279]
[PMID: 30060279]
[30]
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A. 2013 ESC guidelines on the management of stable coronary artery disease: The task force on the management of stable coronary artery disease of the european society of cardiology. Eur Heart J 2013; 34(38): 2949-3003.
[http://dx.doi.org/10.1093/eurheartj/eht296] [PMID: 23996286]
[http://dx.doi.org/10.1093/eurheartj/eht296] [PMID: 23996286]
[31]
Moťovská Z, Varvařovský I, Ošťádal P. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2017; 59(6): e592-612.
[http://dx.doi.org/10.1016/j.crvasa.2017.10.007]
[http://dx.doi.org/10.1016/j.crvasa.2017.10.007]
[32]
Cascorbi I. Drug interactions--principles, examples and clinical consequences. Dtsch Arztebl Int 2012; 109(33-34): 546-55.
[PMID: 23152742]
[PMID: 23152742]
Article Metrics
23
1